Lannett Shares Banished From NYSE, Trading OTC
OTC Markets ‘Significantly More Limited Than The NYSE’
Executive Summary
Lannett investors and creditors must brace for further bad news after the Philadelphia-based Rx and OTC drug firm was struck from the New York Stock Exchange.
You may also be interested in...
New York Exchange Gives Lannett Six Months To Meet Standards
US-based manufacturer Lannett has received a notice of non-compliance from the NYSE due to price of the company’s share. Lannett insists there is no immediate impact, but the firm is evaluating options, including “transactions that are subject to approval of Lannett’s stockholders.”
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.